Compare KIO & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KIO | AVXL |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | 2400 | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.6M | 397.6M |
| IPO Year | N/A | N/A |
| Metric | KIO | AVXL |
|---|---|---|
| Price | $11.56 | $4.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 136.5K | ★ 4.1M |
| Earning Date | 01-01-0001 | 11-25-2025 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.52 | $2.86 |
| 52 Week High | $13.59 | $14.44 |
| Indicator | KIO | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 38.51 | 36.99 |
| Support Level | $11.67 | $3.96 |
| Resistance Level | $11.65 | $4.88 |
| Average True Range (ATR) | 0.08 | 0.41 |
| MACD | 0.02 | 0.20 |
| Stochastic Oscillator | 39.29 | 55.44 |
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.